AI Revolutionizes Drug Design, Yet Efficacy Remains Uncertain
Isomorphic Labs' IsoDDE revolutionizes drug design, but efficacy remains uncertain as no AI-designed drugs have FDA approval.
Isomorphic Labs has made a significant leap in AI-driven drug design with IsoDDE, which integrates protein structure prediction and ligand binding to produce results in seconds. However, the fact that no AI-designed drug has received FDA approval raises questions about the significance of this advancement. The pharmaceutical industry is investing in AI designs but remains cautious due to the uncertainty of outcomes.
This synthesis was produced from its source by AI; there is no human editor or manual review step. How we work